Cardiology

A post hoc ATTRibute-CM analysis examined cardiovascular outcomes and changes in NT-proBNP among women receiving acoramidis.

A post hoc ATTRibute-CM analysis examined whether the Day 28 eGFR dip affected acoramidis outcomes through 30 months.

A retrospective study compared clinical outcomes after patients with ATTR-CM started acoramidis or tafamidis.

A post hoc ATTRibute-CM analysis examined days lost to death or cardiovascular hospitalization with acoramidis versus placebo.

A 1-year interim analysis of a phase 3, multicenter, open-label, 156-week extension study found overall reductions in systolic and diastolic blood pressure with atogepant 60 mg once daily in persons with...

The HF Stats 2026 report examines US heart failure trends, highlighting rising mortality, younger patients, and gaps in treatment.

HFSA 2026 will spotlight late-breaking trials in heart failure drugs, amyloidosis imaging, cardiomyopathy, and device-based care.

Study compares the American Heart Association/American College of Cardiology/multisociety 2026 and 2018 lipid guidelines to assess changes in US eligibility for primary prevention statin therapy.

In an open-label extension, cliramitug reduced cardiac amyloid markers over a median 29.3 months in 23 men with ATTR-CM.

In a post hoc analysis of the randomized CLEAR Outcomes trial, bempedoic acid 180 mg reduced first major adverse limb events (MALE) by 36% and total MALE by 45% versus placebo among statin-intolerant...